These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 8751262

  • 21. Comparable evaluation of orally active beta-lactam compounds in ampicillin-resistant gram-positive and gram-negative rods: role of beta-lactamases on resistance.
    Cullmann W, Dick W, Stieglitz M, Opferkuch W.
    Chemotherapy; 1988; 34(3):202-15. PubMed ID: 3262045
    [Abstract] [Full Text] [Related]

  • 22. [Comparative antibacterial activity of cefpodoxime against Haemophilus influenzae, Streptococcus pyogenes, Streptococcus pneumoniae and Moraxella catarrhalis].
    Wallrauch-Schwarz C, Milatovic D, Braveny I.
    Arzneimittelforschung; 1994 May; 44(5):668-70. PubMed ID: 8024645
    [Abstract] [Full Text] [Related]

  • 23. [Clinical and bacteriological effects of cefetamet pivoxil against community-acquired respiratory tract infections. Part II].
    Shimada J, Ishihara R, Suzuki Y, Ishii Y, Nakazawa A, Deguchi K.
    Jpn J Antibiot; 1997 Sep; 50(9):756-67. PubMed ID: 9394236
    [Abstract] [Full Text] [Related]

  • 24. In vitro susceptibility of Haemophilus influenzae to cefaclor, cefixime, cefetamet and loracarbef.
    Williams JD, Powell M, Fah YS, Seymour A, Yuan M.
    Eur J Clin Microbiol Infect Dis; 1992 Aug; 11(8):748-51. PubMed ID: 1425737
    [Abstract] [Full Text] [Related]

  • 25. In vitro activity and beta-lactamase stability of two oral cephalosporins, ceftetrame (Ro 19-5247) and cefetamet (Ro 15-8074).
    Neu HC, Chin NX, Labthavikul P.
    Antimicrob Agents Chemother; 1986 Sep; 30(3):423-8. PubMed ID: 3490827
    [Abstract] [Full Text] [Related]

  • 26. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
    Pfaller MA, Farrell DJ, Sader HS, Jones RN.
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. In-vitro activity of FCE 22101 against respiratory tract pathogens with reference to production of beta-lactamases.
    Dornbusch K, Kronvall G, Göransson E, Mörtsell E.
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():31-41. PubMed ID: 2786517
    [Abstract] [Full Text] [Related]

  • 36. In-vitro evaluation of cefpodoxime.
    Valentini S, Coratza G, Rossolini GM, Massidda O, Satta G.
    J Antimicrob Chemother; 1994 Mar; 33(3):495-508. PubMed ID: 8040114
    [Abstract] [Full Text] [Related]

  • 37. Cefetamet pivoxil: a review of its microbiology, toxicology, pharmacokinetics and clinical efficacy.
    Cullmann W, Edwards DJ, Kissling M, Kneer J, Stoeckel K, Urwyler H.
    Int J Antimicrob Agents; 1992 Mar; 1(4):175-91. PubMed ID: 18611503
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.